ClinicalTrials.gg
Active, not recruitingNCT06837454FRAMEUpdated Sep 28, 2026

French Prospective Observational Study in Patients Eligible for Systemic Therapy for Atopic Dermatitis (AD)

An observational study in Atopic Dermatitis, sponsored by Sanofi. Active, not recruiting at 61 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Sanofi · Observational

How we know

Updated Sep 28, 2026Now Active, not recruiting11 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
600
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Dermatitis, Atopic by Sanofi — 5 open to participants now, 16 under way, 4 of them phase 3. Dermatitis, Atopic · Sanofi.

Planned enrollment
4th of 15
600 · median 266
Started
2025
with 2 others
Observational
15 of 43
3 open now
Primary completion
2027-05
later than 5 of 15 live
Registered
39th of 43
by date

Among the 43 studies in Dermatitis, Atopic by Sanofi, this one is the 4th largest by planned enrollment of the 15 observational ones that give a count, is one of 3 that started in 2025, is one of 15 observational ones, reaches primary completion later than 5 of the 15 other live ones, and was the 39th registered.

Dermatitis, Atopic

1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

5 of the 43 studies in Dermatitis, Atopic by Sanofi are open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Dermatitis, Atopic by Sanofi, or all of them as a file.
02

Study summary

The objective of the study is to describe the therapeutic management of patients more than or equal to 18 years old eligible for systemic therapy or treated by systemic therapy for atopic dermatitis (AD). This study will be proposed to a sample of French dermatologists experienced in the management of AD, practicing in hospital centers and/or office-based dermatologists. The study will be conducted in real conditions of practice, systemic treatment decisions will be taken at the sole initiative of the participating physician irrespective of the patient enrollment decision. Each patient will be followed-up in routine care setting for 1 year.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients participating in this study will be more than equal to (≥) 18 years old, managed in France for moderate to severe AD, and who are either eligible to systemic treatment or currently under systemic treatment, in realworldsettings within the inclusion period.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed form.
  • Patient with moderate to severe AD according to the Investigator's judgment and

    1. Patient eligible to systemic treatment as Atopic Dermatitis Control Tool (ADCT) more than or equal to (≥) 7 and/or use topical (TCS) more than (>) 90 gram (g)/month and/or TCS are not advisable.

      or

    2. Patient currently under systemic treatment.
  • Able to understand and complete study-related questionnaires.

Exclusion criteria

Exclusion Criteria:

  • Any condition that, in the opinion of the Investigator, may interfere with patient's ability to participate in the study, such as short , substance abuse, severe cognitive impairment, or other comorbidities that can predictably prevent the patient from adequately completing, as per routine care, the schedule of visits and assessments
  • Patient receiving systemic therapy only for a disease other than AD.
  • Patient participating in any interventional clinical trial at the time of enrolment.
  • Patient is under tutorship or curatorship; patient under safeguard of justice or deprived of his/her liberty by an administrative or court decision

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
600 participants (estimated)
Patient registry
No

Groups and cohorts

  • Atopic Dermatitis

    The study plans to collect information on patients during visits according to clinical practice. Enrolled patients will receive AD treatment of marketed drugs prescribed by the specialty physician. No investigational drug will be given for the purpose of this study.

06

What researchers measure

Primary outcomes

  1. Previous and Current Treatments for Atopic Dermatitis (AD)

    List of previous and current treatments for AD based on physician-reported data will be assessed.

    Time frame: Baseline, month 6 and month 12

  2. Atopic Comorbidities: Previous and Current Therapeutic Management

    Description of previous and current therapeutic management of atopic comorbidities over time based on physician-reported data will be assessed.

    Time frame: Baseline, month 6 and month 12

  3. Change from Baseline in Drug Survival for Systemic Treatments for AD by Name and Dose

    Drug survival is defined as the time from the start of treatment to the end or discontinuation of treatment with no changes. If a patient has multiple drug survival events for the same treatment, the longest drug survival will be used in the data summarization. The drug survival will be illustrated using a Kaplan-Meier plot.

    Time frame: Baseline, month 6 and month 12

  4. Compliance for AD Treatments

    Compliance for AD treatments will be assessed by the physician.

    Time frame: Baseline, month 6 and month 12

Secondary outcomes

  1. Demographic Characteristics of Participants

    Demographics characteristics including birth date, gender, and socio-professional category, height, weight, phototype (type I to type VI according to Fitzpatrick's classification).

    Time frame: Baseline

  2. Medical History and AD history

    Medical history will be summarized using the Medical Dictionary for Regulatory Activities (MedDRA) codes of System Organ Class (SOC) and Preferred Terms (PT).

    Time frame: Baseline

  3. Change from Baseline in AD Severity

    Change from baseline in AD severity assessed through physician-reported persistence with prescribed therapy.

    Time frame: Baseline, month 6 and month 12

  4. Atopic Comorbidities

    Description of the presence, evolution, and therapeutic management of atopic comorbidities over time based on physician-reported data.

    Time frame: Baseline, month 6 and month 12

  5. Non-atopic Comorbidities

    Description of the presence, evolution, and therapeutic management of non-atopic comorbidities over time based on physician-reported data.

    Time frame: Baseline, month 6 and month 12

  6. Use of Psychoactive Substances

    Description of the use of psychoactive substances over time based on patient-reported data.

    Time frame: Baseline, month 6 and month 12

  7. Change from Baseline in Itch Assessment

    Itch assessment (Worst-Itch Numeric Rating Scale, WI-NRS) will be rated from 0 to 10 on average during the past 7 days, completed by the observing physician after questioning of patient; 0 = no itch and 10 = the worst imaginable itch.

    Time frame: Baseline, month 6 and month 12

  8. Change from Baseline in Sleep Disturbance NRS

    NRS sleep disturbance will be rated from 0 to 10 on average during the past 7 days, completed by the observing physician after questioning of patient; 0 = "sleep not disturbed at all" (best possible sleep) and 10 = "sleep extremely disturbed (worst possible sleep)".

    Time frame: Baseline, month 6 and month 12

  9. Change from Baseline in Skin Pain NRS

    Skin pain NRS will be rated from 0 to 10 on average during the past 7 days prior to the visit. On a scale of 0 to 10, with 0 being 'no skin pain at all' and 10 being 'the worst imaginable skin pain'.

    Time frame: Baseline, month 6 and month 12

  10. Change from Baseline in AD Disease Control Using the Atopic Dermatitis Control Tool (ADCT)

    ADCT is a questionnaire to assess patient-self-perceived control of their AD with a total score from 0 to 24; higher scores indicate lower AD control.

    Time frame: Baseline, month 6 and month 12

  11. Change from Baseline in Dermatology Life Quality Index (DLQI)

    DLQI is a 10-item questionnaire to measure dermatology specific quality of life (QoL). DLQI is calculated by adding the score of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired. A score higher than 10 indicates that the patient's life is being severely affected by their skin disease.

    Time frame: Baseline, month 6 and month 12

  12. Change from Baseline in Psychological Comorbidities Assessed using Hospital Anxiety and Depression Scale (HADS)

    The HADS is a 14-item patient-reported outcomes measure used to assess states of anxiety and depression over the past week. It is comprised of 7 items assessing anxiety and depression respectively. A Total score is out of 42 (21 per subscale). Higher scores indicate greater levels of anxiety and/or depression.

    Time frame: Baseline, month 6 and month 12

  13. Cumulative Life Course Impairment (CLCI) - for Physicians in Hospital Centers

    CLCI-r instrument determines retrospectively which changes and effects the patients have already experienced due to the disease over their entire disease course. CLCI-p determines the patient's current situation and thus identifies risk areas in which the patient could experience burdens in the future.

    Time frame: Baseline, month 6 and month 12

  14. Change from Baseline in Patient's Treatment Satisfaction Score Using the Patient Global Assessment of Treatment Effect (PGATE)

    Patient's treatment satisfaction score will be assessed using Patient Global Assessment of Treatment Effect (PGATE). PGATE is an assessment tool used to rate the treatment effect of the medication on atopic dermatitis (AD), with scores ranging from 0 to 4 (0 = poor; 1 = fair; 2 = good; 3 = very good; 4 = excellent), i.e., higher score indicated higher treatment effect.

    Time frame: Baseline, month 6 and month 12

  15. Evolution of Atopic Comorbidities

    Evolution of atopic comorbidities over time, assessed through physician-reported status, occurrence of new diagnoses and persistence of existing conditions.

    Time frame: Baseline, month 6 and month 12

  16. Management of AD from First Diagnosis

    History of healthcare pathway of participant related to AD will be assessed by the physician (if participant had appointment with other healthcare provider for AD).

    Time frame: Baseline, month 6 and month 12

  17. Therapeutic Education

    History of healthcare pathway of participant related to AD will be assessed by the physician (if participant received therapeutic education).

    Time frame: Baseline, month 6 and month 12

  18. Cost of Emollients and Hygiene Products

    Cost of emollients, hygiene products etc. during the last month of the study visit will be assessed.

    Time frame: At month 12

  19. Sick Leaves Related to AD

    Number of sick leaves participant has taken related to AD since the last visit or over the last 6 months.

    Time frame: Baseline, month 6 and month 12

  20. Hospitalization with Overnight Stay Related to AD

    Overnight hospitalization related to AD since the last visit or over the last 6 months.

    Time frame: Baseline, month 6 and month 12

07

Study locations

61 sites
  • Investigational Site Number: 2500051
    Aix-en-Provence, 13100, France
  • Investigational Site Number: 2500023
    Amiens, 80000, France
  • Investigational Site Number: 2500004
    Angers, 49000, France
  • Investigational Site Number: 2500017
    Angers, 49100, France
  • Investigational Site Number: 2500050
    Arès, 33740, France
  • Investigational Site Number: 2500054
    Bayonne, 64100, France
  • Investigational Site Number: 2500043
    Bezannes, 51430, France
  • Investigational Site Number: 2500040
    Biarritz, 64200, France
  • Investigational Site Number: 2500036
    Bordeaux, 33000, France
  • Investigational Site Number: 2500053
    Bordeaux, 33000, France
  • Investigational Site Number: 2500061
    Boulogne-Billancourt, 92100, France
  • Investigational Site Number: 2500013
    Chalon-sur-Saône, 71100, France
  • Investigational Site Number: 2500026
    Chalon-sur-Saône, 71100, France
  • Investigational Site Number: 2500046
    Chalon-sur-Saône, 71100, France
  • Investigational Site Number: 2500041
    Châlons-en-Champagne, 51005, France
  • nvestigational Site Number: 2500018
    Cherbourg, 50102, France
  • Investigational Site Number: 2500020
    Cholet, 49300, France
  • Investigational Site Number : 2500048
    Clermont-Ferrand, 63100, France
  • Investigational Site Number: 2500059
    Contamine-sur-Arve, 74130, France
  • Investigational Site Number: 2500010
    Dunkirk, 59385, France
  • Investigational Site Number: 2500047
    Estrées-Deniécourt, 80200, France
  • Investigational Site Number: 2500049
    Fort-de-france, 97261, France
  • Investigational Site Number: 2500032
    La Ravoire, 73490, France
  • Investigational Site Number: 2500044
    La Ravoire, 73490, France
  • Investigational Site Number : 2500011
    La Roche-sur-Yon, 85925, France
  • Investigational Site Number: 2500037
    La Tronche, 38700, France
  • Investigational Site Number: 2500056
    Le Mans, 72000, France
  • Investigational Site Number: 2500068
    Le Mans, 72000, France
  • Investigational Site Number : 2500001
    Le Mans, 72037, France
  • Investigational Site Number: 2500012
    Le Puy-en-Velay, 43000, France
  • Investigational Site Number: 2500003
    Limoges, 87042, France
  • Investigational Site Number: 2500031
    Loperhet, 29470, France
  • Investigational Site Number: 2500067
    Mantes-la-Jolie, 78201, France
  • Investigational Site Number: 2500060
    Marseille, 13012, France
  • Investigational Site Number : 2500069
    Marseille, 13885, France
  • Investigational Site Number: 2500055
    Monaco, 98000, France
  • Investigational Site Number : 2500058
    Mont-de-Marsan, 40024, France
  • Investigational Site Number: 2500033
    Niort, 79021, France
  • Investigational Site Number: 2500065
    Paris, 75005, France
  • Investigational Site Number: 2500005
    Paris, 75009, France
  • Investigational Site Number: 2500030
    Paris, 75010, France
  • Investigational Site Number: 2500071
    Paris, 75017, France
  • Investigational Site Number: 2500009
    Paris, 75020, France
  • Investigational Site Number: 2500028
    Périgueux, 24000, France
  • Investigational Site Number: 2500027
    Périgueux, 24019, France
  • Investigational Site Number: 2500029
    Rennes, 35000, France
  • Investigational Site Number: 2500035
    Rennes, 35000, France
  • Investigational Site Number : 2500021
    Romans-sur-Isère, 26102, France
  • Investigational Site Number : 2500022
    Rouen, 76031, France
  • Investigational Site Number: 2500025
    Saint-Etienne, 42100, France
  • Investigational Site Number: 2500076
    Saint-Martin, 97150, France
  • Investigational Site Number: 2500034
    Saint-Maur-des-Fossés, 94100, France
  • Investigational Site Number: 2500045
    Saint-Quentin, 02321, France
  • Investigational Site Number: 2500057
    Sainte-Eulalie, 15140, France
  • Investigational Site Number: 2500019
    Sainte-Maxime, 83120, France
  • Investigational Site Number: 2500015
    Toulouse, 31200, France
  • Investigational Site Number: 2500016
    Tours, 37044, France
  • Investigational Site Number: 2500038
    Vannes, 56000, France
  • Investigational Site Number: 2500024
    Villefranche-sur-Saône, 69655, France
  • Investigational Site Number : 2500066
    Villeurbanne, 69100, France
  • Investigational Site Number: 2500052
    Villeurbanne, 69100, France
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for May 2027, 27 months after the start.

Of 74 industry-sponsored observational studies under Dermatitis, Atopic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 84. This study's planned 27 months is below that.

Counting every sponsor, half of 172 studies reached it within 47 months; a quarter within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2025
First posted
Feb 20, 2025
StartActual
Feb 4, 2025
Primary completionEst.
May 13, 2027
CompletionEst.
May 13, 2027
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Sep 28, 2026
Sites
11 sites added, 12 sites removed
Show 11 added (11 France)
  • Investigational Site Number: 2500061 · Boulogne-Billancourt, France
  • nvestigational Site Number: 2500018 · Cherbourg, France
  • Investigational Site Number : 2500048 · Clermont-Ferrand, France
  • Investigational Site Number : 2500011 · La Roche-sur-Yon, France
  • Investigational Site Number : 2500001 · Le Mans, France
  • Investigational Site Number: 2500067 · Mantes-la-Jolie, France
  • Investigational Site Number : 2500069 · Marseille, France
  • Investigational Site Number : 2500058 · Mont-de-Marsan, France
  • Investigational Site Number : 2500021 · Romans-sur-Isère, France
  • Investigational Site Number : 2500022 · Rouen, France
  • Investigational Site Number : 2500066 · Villeurbanne, France
Show 12 removed
  • Investigational Site Number: 2500063 · Arès, France
  • Investigational Site Number: 2500018 · Cherbourg, France
  • Investigational Site Number: 2500048 · Clermond Ferrand, France
  • Investigational Site Number: 2500011 · La Roche-sur-Yon, France
  • Investigational Site Number: 2500001 · Le Mans, France
  • Investigational Site Number: 2500058 · Mont-de-Marsan, France
  • Investigational Site Number: 2500070 · Mont-Saint-Aignan, France
  • Investigational Site Number: 2500021 · Romans-sur-Isère, France
  • Investigational Site Number: 2500022 · Rouen, France
  • Investigational Site Number: 2500062 · Saint-Gervais-les-Bains, France
  • Investigational Site Number: 2500008 · Saint-Maur-dès-Faussés, France
  • Investigational Site Number: 2500066 · Villeurbanne, France
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Recruiting→Active, not recruiting
    11 sites added, 12 sites removed
    Show 11 added (11 France)
    • Investigational Site Number: 2500061 · Boulogne-Billancourt, France
    • nvestigational Site Number: 2500018 · Cherbourg, France
    • Investigational Site Number : 2500048 · Clermont-Ferrand, France
    • Investigational Site Number : 2500011 · La Roche-sur-Yon, France
    • Investigational Site Number : 2500001 · Le Mans, France
    • Investigational Site Number: 2500067 · Mantes-la-Jolie, France
    • Investigational Site Number : 2500069 · Marseille, France
    • Investigational Site Number : 2500058 · Mont-de-Marsan, France
    • Investigational Site Number : 2500021 · Romans-sur-Isère, France
    • Investigational Site Number : 2500022 · Rouen, France
    • Investigational Site Number : 2500066 · Villeurbanne, France
    Show 12 removed
    • Investigational Site Number: 2500063 · Arès, France
    • Investigational Site Number: 2500018 · Cherbourg, France
    • Investigational Site Number: 2500048 · Clermond Ferrand, France
    • Investigational Site Number: 2500011 · La Roche-sur-Yon, France
    • Investigational Site Number: 2500001 · Le Mans, France
    • Investigational Site Number: 2500058 · Mont-de-Marsan, France
    • Investigational Site Number: 2500070 · Mont-Saint-Aignan, France
    • Investigational Site Number: 2500021 · Romans-sur-Isère, France
    • Investigational Site Number: 2500022 · Rouen, France
    • Investigational Site Number: 2500062 · Saint-Gervais-les-Bains, France
    • Investigational Site Number: 2500008 · Saint-Maur-dès-Faussés, France
    • Investigational Site Number: 2500066 · Villeurbanne, France
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06837454
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Feb 20, 2025
Start date
Feb 4, 2025
Primary completion
May 13, 2027 (estimated)
Completion
May 13, 2027 (estimated)
Last update
Sep 28, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion